NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Revna Biosciences

Revna Biosciences

Private
AccraHealthcare & Life Scienceshttps://revnabio.com/

Last Round

Growth Equity

Mar 1, 2026

Total Funding Raised

$118,000

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Revna Biosciences is a biotechnology company that provides precision medicine services, advanced molecular diagnostics, and biobanking infrastructure in Africa.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Usage-Based SaaS, Services & Consulting

AI Layer

Non-AI

Keywords

molecular diagnosticsgenomic sequencingclinical laboratoryoncology diagnosticsinfectious disease testingbiobankingpharmacogeneticsclinical research servicesgenomics labdiagnostic labwhole genome sequencingWGSwhole exome sequencingWESprecision medicineclinical bioinformatics

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Revna Biosciences Comparables

Compare Revna Biosciences with similar companies based on industry and business-model similarity.

Revna Biosciences comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Yemaachi Biotechnology
84%
Roche Holding
63%
Nalagenetics
57%

Revna Biosciences Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Growth EquityMar 1, 2026
VC RoundDec 1, 2024
GrantMar 27, 2024
GrantAug 24, 2023
SeedNov 11, 2022

Key People

Founding team and executive leadership

Derrick Edem Akpalu

CEO & Co-Founder

Founding Team

Revna Biosciences Investors

Notable investors and investment history

Revna Biosciences investors
InvestorRounds
Aruwa Capital ManagementVC Round
Jaza Rift VenturesSeed
African Diaspora NetworkSeed, Grant
develoPPP VenturesGrant
Mirepa CapitalGrowth Equity
develoPPPGrant
Tekedia CapitalSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 23, 2026

    Grew 23% QoQ, from 26 to 32 employees.

  • Mar 2, 2026

    Monthly visitors increased 439% MoM, reaching 248.

Revna Biosciences Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Revna Biosciences Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Revna Biosciences's valuation, stock price, and market status.

Firmographic Details

HeadquartersAccra
Employee Range31
Year Founded2017
Last FundingMar 1, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.